The latest changes to R&D tax credits

R&D tax credits

Date:

Category:

Share this article:

In an effort to boost productivity growth, the Government has set a target to raise investment in Research & Development (R&D) to 2.4% of UK GDP by 2027. The Chancellor Jeremy Hunt, emphasised that the Spring 2023 budget was focused on growth. Encouraging more R&D projects is key to this goal and a number of key changes were announced to the current R&D tax relief scheme in order to support innovation.

One of the headline announcements was a cut in the enhancement rate from 130% to 86% and the tax credit rate is being reduced from 14.5 % to 10%. The RDEC scheme will see an increase from 13% to 20%. Many of these changes are in response to the reports of abuse and fraud of the R&D SME scheme and the need to focus the R&D tax relief scheme on being more attractive to larger businesses and reducing the relief for SME’s. The two schemes may be merged into one in the future.

Data licences and cloud computing services will now be listed as two new expenditure categories. The planned inclusion of international R&D expenditure will now be delayed until 1 April 2024. There will also be a new credit will be available to loss-making SME’s where the R&D expenditure is at least 40% of total spend. 

A new digital form is being implemented from within 6 months of the end of the accounting period in which the expenditure is incurred. This will enable HMRC to carry out more upfront compliance checks.

Jon Goodier, R&D Director said “It’s good to see that the Government recognises the importance of rewarding innovation in the UK. The two new expenditure categories are very welcomed as this will provide more support to newly developed industries.”

Speak to an expert

If you need support with anything R&D tax related, then get in touch with the Xeinadin R&D team and we’ll start working with you straight away. Our aim to help you through the entire process and ensure you are maximising the amount of R&D tax credit that you can claim. 

This website uses cookies

With these cookies, we and third parties can collect information about you and your internet behaviour, both within and outside our website. Based on this, we and third parties adjust the website, our communication, and advertisements to your interests and profile. You can read more information in our cookie statement.

If you opt for acceptance, we will place all cookies. If you opt for rejection, we will only place functional and analytical cookies. You can adjust your preferences at a later time.

Accept Reject More options

This website uses cookies

With these cookies, we and third parties can collect information about you and your internet behaviour, both within and outside our website. Based on this, we and third parties adjust the website, our communication, and advertisements to your interests and profile. You can read more information in our cookie statement.

Functional cookies
Arrow down

Functional cookies are essential for the proper functioning of our website. They allow us to enable basic functions such as page navigation and access to secure areas. These cookies do not collect personal information and cannot be disabled.

Analytical cookies
Arrow down

Analytical cookies help us gain insight into how visitors use our website. We collect anonymised data about page interactions and navigation, enabling us to continuously improve our site.

Marketing cookies
Arrow down

Marketing cookies are used to track visitors when they visit different websites. The goal is to display relevant advertisements to the individual user. By allowing these cookies, you help us show you relevant content and offers.

Accept all Save

Name

Subtitle
Developer
Location
They are focussed on creating a future-focused and relationship-driven culture, that keeps its promises to you, our team members, and partners.
Xeinadin